Metabotropic glutamate receptor 2 activators

Topics in Medicinal Chemistry

Volumn 13, Issue , 2015, Pages 101-142

  Cid, José M ^a   Trabanco, Andreś A ^a   Lavreysen, Hilde ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Metabotropic glutamate receptor 2; mGlu2; PAM; Positive allosteric modulator; Potentiator

Indexed keywords

ACETOPHENONE DERIVATIVE; ALPRAZOLAM; ATYPICAL ANTIPSYCHOTIC AGENT; AZD 8529; BENZIMIDAZOLE DERIVATIVE; BENZOTRIAZOLE DERIVATIVE; CARBAMIC ACID DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; IMIDAZOPYRIDINE DERIVATIVE; INDANONE DERIVATIVE; INDOLE DERIVATIVE; JNJ 40411813; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PLACEBO; POMAGLUMETAD METHIONIL; PROLACTIN; PYRIDONE DERIVATIVE; RISPERIDONE; SULFONAMIDE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BODY WEIGHT DISORDER; COGNITIVE DEFECT; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HIGH THROUGHPUT SCREENING; HUMAN; HYPERACTIVITY; MAJOR DEPRESSION; METABOLIC SYNDROME X; MONOTHERAPY; NEGATIVE SYNDROME; NONHUMAN; PANIC; PLASMA CLEARANCE; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84921744649     PISSN: 18622461     EISSN: 1862247X     Source Type: Book Series    
DOI: 10.1007/7355_2014_48     Document Type: Article

References (166)

1. Rossler W, Joachim SH, van Os J et al (2005) Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 15:399-409
2. Macdonald GJ, Bartolomé JM (2010) A decade of progress in the discovery and development of ‘Atypical’ antipsychotics. Prog Med Chem 49:37-80
3. Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-330
4. Davidson M, Galderisi S, Weiser M et al (2009) Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-lab clinical trial (EUFEST). Am J Psychiatry 166:675-682
5. Green MF, Kern RS, Heaton RK et al (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72:41-51
6. Carpenter WT Jr, Buchanan RW, Conley RR (1998) Pharmacotherapy of schizophrenia. In: Pharmacological management of neurological and psychiatric disorders. McGraw-Hill, New York, pp 27-51
7. Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl 1):1
8. Miyamoto S, Duncan GE, Marx CE et al (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79-104
9. Lahti AC, Weiler MA, Tamara Michaelidis BA et al (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25:455-467
10. Conn PJ, Lindsley CW, Jones CK (2008) Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 30:25-31
11. Moghaddam B (2004) Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology 174:39-44
12. Vinson PN, Conn PJ (2012) Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacology 62:1461-1472
13. Theberge J, Bartha R, Drost DJ et al (2002) Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 159:1944-1946
14. Theberge J, Al-Semann Y, Williamson PC et al (2003) Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 160:2231-2233
15. Marsman A, van den Heuvel MP, Klomp DWJ et al (2013) Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophr Bull 39:120-129
16. Schosser A, Aschauer HN (2004) In search of susceptibility genes for schizophrenia. Wiener Klinische Wochenschrift 116:27-833
17. Makino C, Shibata H, Ninomiya H et al (2005) Identification of single-nucleotide polymorphisms in the human N-methyl-D-aspartate receptor subunit NR2D gene, GRIN2D, and association study with schizophrenia. Psychiatr Genet 15:215-221
18. Lisman JE, Coyle JT, Green RW et al (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31:234-242
19. Kew JN, Kemp JA (2005) Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 179:4-29
20. Brauner-Osborne H, Wellendorph P, Jensen AA (2007) Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors. Curr Drug Targets 8:169-184
21. Schoepp DD, Jane DE, Monn JA (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38:1431-1476
22. Swanson CJ, Bures M, Johnson MP et al (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4:131-144
23. Fell MJ, Svensson KA, Johnson BG et al (2008) Evidence for the role of mGlu2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039. J Pharm Exp Ther 326:209-217
24. Woolley ML, Pemberton DJ, Bate S et al (2008) The mGlu2 but not the mGlu3 receptor mediates the actions of the mGlu2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology 196:431-440
25. Monn JA, Valli MJ, Massey SM et al (1997) Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2, 6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 40:528-537
26. Pellicciari R, Marinozzi M, Natalini B et al (1996) Synthesis and pharmacological characterization of all sixteen stereoisomers of 2-(20-carboxy-30-phenylcyclopropyl)glycine. Focus on (2S, 10S, 20S, 30R)-2-(20-carboxy-30-phenylcyclopropyl)glycine, a novel and selective group II metabotropic glutamate receptors. J Med Chem 39:2259-2269
27. Pellicciari R, Costantino G, Marinozzi M et al (2001) Design, synthesis and preliminary evaluation of novel 30-substituted carboxycyclopropylglicines as antagonists at group 2 metabotropic glutamate receptors. Bioorg Med Chem Lett 11:3179-3182
28. Fell MJ, McKinzie DL, Monn JA et al (2012) Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 62:1473-1483
29. Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352
30. Cartmell J, Schoepp DD (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75:889-907
31. Imre G (2007) The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268. CNS Drug Rev 13:444-464
32. Patil ST, Zhang L, Martenyi F et al (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase II clinical trial. Nature Med 13:1102-1107
33. Kinon BJ, Gómez JC (2013) Clinical development of pomaglumetad methionil: A non-dopaminergic treatment for schizophrenia. Neuropharmacology 66:82-86
34. Kinon BJ, Zhang L, Millen BA et al (2011) A multicenter, inpatient, Phase II, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 31:349-355
35. Stauffer VL, Millen BA, Andersen S et al (2013) Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res 150:434-441
36. Eli Lilly and Co. (2012) Lilly Stops Phase III development of pomaglumetad methionil for the treatment of Schizophrenia based on efficacy results. https://investor.Lilly.com/releaseDetail.cfm ReleaseID=703018
37. Galici R, Echemendia NG, Rodriguez AL et al (2005) A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharm Exp Ther 315:1181-1187
38. Conn PJ, Christopoulos A, Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54
39. Johnson MP, Baez M, Jagdmann GE et al (2003) Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2, 2, 2-trifluoroethylsulfonyl)pyrid-3-yl-methylamine. J Med Chem 46:3189-3192
40. Johnson MP, Barda D, Britton TC et al (2005) Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology 179:271-283
41. Rodriguez D (2004) Attenuation of ketamine-induced hyperactivity responses in rats following administration of a novel metabotropic glutamate receptor 2 selective positive modulator. In: Proceedings of the annual meeting of the society for neuroscience; Oct 23-27; Abstract number 798.8, Dallas, TX. Society for Neuroscience, Washington, DC
42. Galici R, Jonas CK, Hemstapat K et al (2006) Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic-and anxiolytic-like effects in mice. J Pharm Exp Ther 318:173-185
43. Bonnefous C, Vernier JM, Hutchinson JH et al (2005) Biphenyl-indanones: allosteric potentiators of metabotropic glutamate subtype 2 receptor. Bioorg Med Chem Lett 15:4354-4358
44. Pinkerton AB, Vernier JM, Schaffhauser H et al (2004) Phenyl-tetrazolyl acetophenones: discovery of allosteric potentiators for the metabotropic glutamate 2 receptor. J Med Chem 47:4595-4599
45. Pinkerton AB, Cube RV, Hutchinson JH et al (2004) Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 1: identification and synthesis of phenyltetrazolyl acetophenones. Bioorg Med Chem Lett 14:5329-5332
46. Pinkerton AB, Cube RV, Hutchinson JH et al (2004) Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 2: 4-thiopyridyl acetophenones as nontetrazole-containing mGlu2 receptor potentiators. Bioorg Med Chem Lett 14:5867-5872
47. Cube RV, Vernier JM, Hutchinson JH et al (2005) 3-2-ethoxy-4-4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy] butoxy phenylpropanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2). Bioorg Med Chem Lett 15:2389-2393
48. Govek SP, Bonnefous C, Hutchinson JH et al (2005) Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in animal model for schizophrenia. Bioorg Med Chem Lett 15:4068-4072
49. Cid JM, Duvey G, Cluzeau P et al (2010) Discovery of 1, 5-disubstituted pyridines: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor. ACS Chem Neurosci 1:788-795
50. Cid JM, Duvey G, Tresadern G et al (2012) Discovery of 1, 4-disubstituted 3-cyano-2-pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor. J Med Chem 55:2388-2405
51. Clayton J, Ma F, Van Wagenen B et al (2006) Preparation of isoindolones as metabotropic glutamate receptor potentiators. WO 2006/020, 879
52. Van Wagenen B, Ukkiramapandian R, Clayton J et al (2007) Preparation of metabotropic glutamate-receptor-potentiating isoindolones. WO 2007/021, 308
53. Balestra M, Bunting H, Chen D et al Preparation of pyrazolones as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders. WO 2006/ 071730, 6 July 2006.
54. Imogai H, Duvey GAJ, Cid-Núñez JM et al Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mGlu2-receptors. WO 2006/ 030031, 23 Mar 2006.
55. Duplantier AJ, Efremov I, Candler J et al (2009) 3-Benzyl-1, 3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: hit to lead and lead optimization. Bioorg Med Chem Lett 19:2524-2529
56. Brnardic EJ, Fraley ME, Garbaccio RM et al (2010) 3-Aryl-5-phenoxymethyl-1, 3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: hit-to-lead efforts. Bioorg Med Chem Lett 20:3129-3133
57. Zhang L, Rogers BN, Duplantier AJ et al (2008) 3-(Imidazolyl methyl)-3-aza-bicyclo [3.1.0] hexan-6-yl methyl ethers: a novel series of mGluR2 positive allosteric modulators. Bioorg Med Chem Lett 18:5493-5496
58. D’Alessandro PL, Corti C, Roth A et al (2010) The identification of structurally novel, selective, orally bioavailable positive allosteric modulators of mGluR2. Bioorg Med Chem Lett 20:759-762
59. Zhang L, Brodney MA, Candler J et al (2011) 1-[(1-Methyl-1H-imidazol-2-yl)methyl]4-phenylpiperidines as mGluR2 positive allosteric modulators for the treatment of psychosis. J Med Chem 54:1724-1739
60. Cao B, Gurunian V, Kongsamut S et al (2008) Substituted dihydro-and tetrahydrooxazolopyrimidones, preparation and use as metabotropic glutamate receptor modulators. WO 2008/112, 483
61. Sheffler DJ, Pinkerton AB, Dahl R et al (2011) Recent progress in the synthesis and characterization of group II metabotropic glutamate receptor allosteric modulators. ACS Chem Neurosci 2:382-393
62. Rudd MT, McCauley JA (2005) Positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGluR2). Curr Top Med Chem 5:869-884
63. Fraley ME (2009) Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Patents 19:1259-1275
64. Marek, GJ, Kinon BJ, McKinzie DL et al (2012) Metabotropic glutamate 2/3 receptor agonists and positive allosteric modulators of metabotropic glutamate receptor 2 as novel agents for the treatment of schizophrenia. Targets and Emerging Therapies for Schizophrenia 143-185
65. Trabanco AA, Cid JM, Lavreysen H et al (2011) Progress in the development of positive allosteric modulators of the metabotropic glutamate receptor 2. Curr Med Chem 18:47-68
66. Trabanco AA, Cid JM (2013) mGluR2 positive allosteric modulators (PAMs): a patent review (2009-present). Expert Opin Ther Patents 23:629-647
67. ClinicalTrials.gov (2008) ADZ8529 single ascending dose study (SAD). http://clinicaltrials.gov/show/NCT00755378
68. ClinicalTrials.gov (2009) Study to assess the efficacy, safety, and tolerability of ADZ8529 in adult schizophrenia patients. http://clinicaltrials.gov/show/NCT00921804
69. The effects ADZ8529 on cognition and negative symptoms in schizophrenics (2009). http://clinicaltrials.gov/show/NCT00986531
70. Litman RE (2013) AZD8529, A positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study NCDEU An Annual Meeting of the ASCP Westin Diplomat, Hollywood Florida, US May 28-31
71. Study to explore the safety, tolerability and potential clinical efficacy of JNJ-40411813 in schizophrenic patients (2011). http://clinicaltrials.gov/show/NCT01323205
72. Lavreysen H (2013) Discovery and early clinical development of novel mGlu2 receptor PAMs. American College of Neuropsychopharmacology (ACNP) 52nd Annual Meeting, Hollywood, Florida, US, December 10
73. Study to evaluate the efficacy and overall safety and tolerability of treatment with adjunctive JNJ 40411813 compared to placebo in patients with MDD with anxiety symptoms being treated with an antidepressant. http://clinicaltrials.gov/show/NCT01582815
74. Britton T, Barda DA, Hornback WJ et al (2002). Selective, non-amino acid allosteric potentiators of mGlu2 receptors. 223rd ACS National Meeting, Orlando, Florida, US, April 7-11.
75. Barda DA, Wang Z-Q, Britton TC, Henry SS et al (2004) SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide. Bioorg Med Chem Lett 14:3099-3102
76. Schaffhauser H, Rowe BA, Morales S et al (2003) Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol 64:798-810
77. Harich S, Gross G, Bespalov A (2007) Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology 192:511-519
78. Nikiforuk A, Popik P, Drescher KU et al (2010) Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats. J Pharm Exp Ther 335:665-673
79. Khilevich A, Liu B, Mayhugh DR et al (2010) Imidazolecarboxamide derivatives as mGlu2 receptor potentiators and their preparation, pharmaceutical compositions and use in the treatment of depression. WO 2010/009, 062
80. Fell MJ, Witkin JM, Falcone JF et al (2011) N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J Pharm Exp Ther 336:165-177
81. Johnson PL, Fitz SD, Engleman EA et al (2013) Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panicvulnerable rats. J Psychopharmacol 27:152-161
82. Pinkerton AB, Vernier JM, Cube RV et al (2006) Preparation of indanone potentiators of metabotropic glutamate receptors for use against neurol. and psychiatric disorders. WO 2006/015, 158
83. Pinkerton, AB, Vernier JM, Cube RV et al (2006) Preparation of heterocyclic indanone potentiators of metabotropic glutamate receptors for the treatment of neurological and psychiatric disorders. WO 2006/047, 237
84. Pinkerton AB, Cube RV, Hutchinson JH et al (2005) Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: identification and biological activity of indanone containing mGlu2 receptor potentiators. Bioorg Med Chem Lett 15:1565-1571
85. Lorrain DS, Schaffhauser H, Campbell UC et al (2003) Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Neuropsychopharmacology 28:1622-1632
86. Benneyworth MA, Xiang Z, Smith RL et al (2007) A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol 72:477-484
87. Ahnaou A, Dautzenberg FM, Geys H et al (2009) Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture. Eur J Pharmacol 603:62-72
88. Hackler EA, Byun NE, Jones CK et al (2010) Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation. Neuroscience 168:209-218
89. Hikichi H, Kaku A, Karasawa J et al (2013) Stimulation of metabotropic glutamate (mGlu) 2 receptor and blockade of mGlu1 receptor improve social memory impairment elicited by MK-801 in rats. J Pharm Sci 122:10-16
90. Govek SP, Vernier JM, Kamenecka T et al (2006) Preparation of benzazole potentiators of metabotropic glutamate receptors. WO 2006/091, 496
91. Van Wagenen B, Ukkiramapandian R, Clayton J et al (2007) Substituted isoindolones as metabotropic glutamate receptor potentiators, their preparation, pharmaceutical compositions, and use in therapy. WO 2007/021, 309
92. Clayton J, Egle I, Empfield J et al (2008) Preparation of metabotropic glutamate receptor oxadiazole ligands and their use as potentiators. WO 2008/150, 232
93. Clayton J, Egle I, Empfield J et al (2008) Preparation of oxadiazole derivatives as metabotropic glutamate receptor potentiators. WO 2008/150, 233
94. Blade H, Cosgrove SD (2011) Polymorphs of metabotropic glutamate receptor positive allosteric modulator. WO 2011/136, 723
95. Boyd A, Fielding MR, Ford JG et al (2011) Process for preparing 7-methyl-5-(3-piperazin-1-ylmethyl-[1, 2, 4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2, 3-dihydroisoindol-1-one, a metabotropic glutamate receptor positive allosteric modulator. WO 2011/084, 098
96. Clayton J, Empfield J, Folmer J et al (2008) Preparation of oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators. US 2008/0, 306, 077
97. Van Wagenen B, Ukkiramapandian R, Clayton J et al (2011) Preparation of substituted isoindolones as metabotropic glutamate receptor potentiators and useful in the treatment of schizophrenia. US 2011/7, 868, 008
98. Cacciola J, Empfield J, Folmer J et al (2009) Preparation of isoxazole derivatives and their use as metabotropic glutamate receptor potentiators. WO 2009/148, 403
99. Slassi A, Isaac M, Clayton J et al (2008) Preparation of aza-isoindolones as metabotropic glutamate receptor potentiators. WO 2008/100, 715
100. Egle I, Slassi A, Isaac M et al (2008) Preparation of hydrazides as metabotropic glutamate receptor potentiators. WO 2008/130, 853
101. Geneste H, Sauer D, Braje W et al (2008) Preparation of heterocyclic compounds, in particular pyrazole derivatives as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor). WO 2008/145, 616
102. Braje W, Jantos K, Geneste H et al Novel small molecule potentiators of metabotropic glutamate receptors. US 2011/0, 245, 232
103. Braje W, Jantos K, Geneste H et al (2011) Novel small molecule potentiators of metabotropic glutamate receptors. US 2011/0, 245, 247
104. Adam J, Gillespie J, Laats S et al (2011) Preparation of isoindolinylbenzylimidazolidine-2, 4-dione derivatives as mGlu2 receptor modulators. WO 2011/051, 490
105. Cosford NDP, Panickar DR, Sidique S (2011) Preparation of cycloalkyloxoisoindolinylbiphenylcarboxylic acid derivatives and analogs for use as metabotropic glutamate subtype 2 receptor positive allosteric modulators. WO 2011/116, 356
106. Dhanya R-P, Sidique S, Sheffler DL et al (2011) Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem 54:342-353
107. Sidique S, Dhanya R-P, Sheffler DL et al (2012) Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence. J Med Chem 55:9434-9445
108. Imogai H, Cid-Núñez JM, Duvey GAJ et al (2006) Novel pyridinone derivatives and their preparation, pharmaceutical compositions, and use as positive allosteric modulators of mGlu2 receptors for treatment of various neurological and psychiatric disorders. WO 2006/030, 032
109. Trabanco AA, Duvey G, Cid JM et al (2011) New positive allosteric modulators of the metabotropic glutamate receptor 2 (mGluR2): Identification and synthesis of N-propyl-8-chloro-6-substituted isoquinolones. Bioorg Med Chem Lett 21:971-976
110. Trabanco AA, Duvey G, Cid JM et al (2011) New positive allosteric modulators of the metabotropic glutamate receptor 2 (mGluR2) Identification and synthesis of N-propyl-5-substituted isoquinolones. Med Chem Commun 2:132-139
111. Isaac M, Slasi A, Egle I et al (2007) Preparation of tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators. US 2007/0, 032, 469
112. Egle I, Isaac M, Urbanek R et al (2007) Preparation of benzimidazole derivatives and their use as metabotropic glutamate receptor potentiators. WO 2007/115, 077
113. Berke H, Duplantier AJ, Efremov I et al (2007) Benzimidazolyl compounds as mGluR2 agonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO 2007/135, 527
114. Efremov IV, Rogers BN, Duplantier AJ et al (2008) Azabenzimidazolyl compounds as potentiators of mGlu2 subtype of glutamate receptor and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO 2008/012, 622
115. Efremov IV, Rogers BN, Duplantier AJ et al (2008) Benzimidazolyl compounds as potentiators of mGlu2 subtype of glutamate receptor and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO 2008/012, 623
116. Berke H, Duplantier AJ, Efremov IV et al (2007) Preparation of azabenzimidazoles as glutamate mGluR2 agonists. WO 2007/135, 529
117. Slassi A, Joseph B, Ma F et al (2007) Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators in the treatment of neurological and psychiatric disorders and preparation. WO 2007/078, 523
118. Isaac M, Slassi A, Egle I et al (2008) Preparation of spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators. WO 2008/032, 191
119. Duplantier AJ, Efremov IV, Zhang L et al (2009) Preparation of N-Benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors. WO 2009/ 004, 430
120. Brnardic EJ, Fraley M, Garbaccio R et al (2009) Preparation of 3, 5-substituted-1, 3-oxazolidin-2-one derivatives as potentiators of metabotropic glutamate receptors. WO 2009/094, 265
121. Brnardic EJ, Fraley M, Layton M et al (2010) Preparation of 3, 5-substituted-1, 3-oxazolidin-2-one derivatives as potentiators of metabotropic glutamate receptors. US 2010/0, 292, 241
122. Brnardic EJ, Converso A, Fraley M et al (2009) Preparation of oxazolobenzimidazole derivatives as potentiators of metabotropic glutamate receptors. WO 2009/140, 163
123. Brnardic EJ, Fraley M, Garbaccio RM (2009) Oxazolobenzimidazole derivatives as mGluR inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO 2009/140, 166
124. Garbaccio RM, Brnardic EJ, Fraley ME et al (2010) Discovery of oxazolobenzimidazoles as positive allosteric modulators for the mGlu2 receptor ACS Med Chem Lett 1:406-410
125. Cao B, Gurunian V, Kongsamut S et al (2008) Substituted dihydro-and tetrahydro oxazolopyrimidinones, preparation and use as metabotropic glutamate receptor modulator. WO 2008/112, 483
126. Kosley RW Jr., Sher R (2009) Cycloalkyloxazolopyrimidinone derivatives as metabotropic glutamate receptors modulators and their preparation, pharmaceutical compositions and use in the treatment of central nervous system disorders. WO 2009/110, 901
127. George P, Hall D, Hartung R et al (2011) Preparation of biphenyloxymethyldihydrooxazolopyrimidone derivatives for use as metabotropic glutamate receptor modulators. WO 2011/034, 828
128. Kosley RW Jr., Sher R (2011) Preparation of dihydrobenzocycloalkyloxymethyloxazolopyrimidinone derivatives for use as metabotropic glutamate receptor modulators. WO 2011/034, 830
129. Kosley RW Jr., Sher R, Neuenschwander KW et al (2011) Preparation of phenoxymethyldihydrooxazolopyrimidinone derivatives for use as metabotropic glutamate receptor modulators. WO 2011/034, 832
130. Imogai HJ, Cid-Núñez JM, Andreś-Gil JI et al (2007) 1, 4-Disubstituted 3-cyanopyridone derivatives and their use as positive allosteric modulators of mGlu2-receptors and their preparation. WO 2007/104, 783
131. Cid-Núñez JM, Trabanco-Suárez AA, Macdonald GJ et al (2008) Preparation of 1, 4-disubstituted 3-cyanopyridone derivatives as positive mGlu2 receptor modulators. WO 2008/107, 480
132. Cid-Núñez JM, Trabanco-Suárez AA, Macdonald GJ et al (2008) Preparation of 3-cyano-4-(4-tetrahydropyranphenyl)pyridin-2-one derivatives as positive mGlu2 receptor modulators. WO 2008/107, 481
133. Cid-Núñez JM, Trabanco-Suárez AA, Macdonald GJ et al (2008) Preparation of 3-cyano-4-(4-phenylpiperidin-1-yl)-pyridin-2-one derivatives for treating and preventing neurol. And psychiatric diseases associated with glutamate dysfunction. WO 2008/107, 479
134. Lavreysen H, Langlois X, Ahnaou A et al (2013) Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782. J Pharmacol Exp Ther 346:514-527
135. Cid-Núñez JM, Trabanco-Suárez AA, Macdonald GJ et al (2009) Preparation of disubstituted pyridin-2-ones as positive allosteric modulators of mGluR2 for treating neurological and psychiatric disorders. WO 2009/033, 702
136. Cid-Núñez JM, Trabanco-Suárez AA, Macdonald GJ et al (2009) Preparation of 1, 3-disubstituted-4-phenyl-1H-pyridin-2-ones as positive allosteric modulators of mGluR2 for treating neurological and psychiatric disorders. WO 2009/033, 703
137. Cid-Núñez JM, Trabanco-Suárez AA, Macdonald GJ et al (2009) Preparation of bipyridinones as positive allosteric modulators of mGluR2 for treating neurological and psychiatric disorders. WO 2009/033, 704
138. Cid-Núñez JM, Trabanco-Suárez AA (2010) Preparation of indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors for treating neurological and psychiatric disorders. WO 2010/043, 396
139. Trabanco-Suárez AA, Tresadern GJ, Vega-Ramiro JA et al (2009) Preparation of imidazopyridine derivatives for use as mGlu2 receptor modulators. WO 2009/062, 676
140. Tresadern G, Cid JM, Macdonald GJ et al (2010) Scaffold hopping from pyridines to imidazo [1, 2-a]pyridines. New positive allosteric modulators of metabotropic glutamate 2 receptor. Bioorg Med Chem Lett 20:175-179
141. Cid-Núñez JM, Trabanco-Suárez AA, Macdonald GJ (2010) Preparation of indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors for treating neurological and psychiatric disorders. WO 2010/060, 589
142. Trabanco AA, Tresadern G, Macdonald GJ et al (2012) Imidazo[1, 2-a]pyridines: orally active positive allosteric modulators of the metabotropic glutamate receptor 2. J Med Chem 55:2688-2701
143. Cid-Núñez JM, Oehlrich D, Trabanco-Suárez AA et al (2010) Preparation of 1, 2, 4-triazolo [4, 3-a]pyridines for the treatment or prevention of neurological and psychiatric disorders. WO 2010/130, 424
144. Cid JM, Tresadern G, Vega JA et al (2012) Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1, 2, 4]triazolo[4, 3a] pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. J Med Chem 55:8770-8789
145. Cid-Núñez JM, Trabanco-Suárez AA, Oehlrich D et al (2012) Preparation of 1, 2, 4-triazolo [4, 3-a]pyridine derivatives and their use as positive allosteric modulators of mGlu2 receptors for treating neurological disorders and psychiatric disorders. WO 2012/062, 750
146. Cid-Núñez JM, Trabanco-Suárez AA, Vega-Ramiro JA et al (2012) Preparation of 1, 2, 4-triazolo[4, 3-a]pyridine derivatives and their use as positive allosteric modulators of mGlu2 receptors for treating neurological disorders and psychiatric disorders. WO 2012/062, 751
147. Cid-Núñez JM, Trabanco-Suárez AA, Vega-Ramiro JA et al (2012) Preparation of 1, 2, 4-triazolo[4, 3-a]pyridine derivatives and their use as positive allosteric modulators of mGlu2 receptors for treating neurological disorders and psychiatric disorders. WO 2012/062, 759
148. Andreś JI, Alcazar J, Cid JM et al (2012) Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging. J Med Chem 55:8685-8699
149. Schmidt M (2012) Human PET imaging with [11C]JNJ-42491293, a tracer for the mGluR2 positive allosteric site. J Cereb Blood Flow Metab 32:S13-S40. doi:10.1038/jcbfm.2012.77
150. Cid-Núñez JM, De Lucas-Olivares AI, Trabanco-Suárez AA et al (2010) 7-Aryl-1, 2, 4-triazolo[4, 3-a]pyridine derivatives as positive allosteric modulators of mGlu2 receptors and their preparation, pharmaceutical compositions and use in the treatment of CNS disorders. WO 2010/130, 423
151. Cid-Núñez JM, De Lucas-Olivares AI, Trabanco-Suárez AA et al (2010) 1, 2, 4-triazolo [4, 3-a]pyridine derivatives as mGlu2 modulators and their preparation and use for the treatment of CNS diseases. WO 2010/130, 422
152. Mattson RJ, Meng Z (2013) Preparation of triazolo[4, 3-a]pyridinamine compounds as positive allosteric modulators of mGluR2 for the treatment of neurological and psychiatric diseases. WO 2013/138, 687
153. Dudkin V, Fraley M, Wang C et al (2010) Preparation of aminobenzotriazole derivatives for use as metabotropic glutamate receptor modulators. WO 2010/114, 726
154. Beshore DC, Dudkin V, Kuduk S et al (2010) Preparation of biaryl benzotriazole derivatives for use as metabotropic glutamate receptor potentiators and useful in treatment of neurological and psychiatric disorders associated with glutamate dysfunction. WO 2010/141, 360
155. Dudkin VY, Fraley ME, Wang C et al (2011) Preparation of ether benzotriazole derivatives for use as metabotropic glutamate receptor potentiators and useful in treatment of neurological and psychiatric disorders associated with glutamate dysfunction. WO 2011/022, 312
156. Beshore DC, Dudkin V, Garbaccio RM et al (2012) Preparation of ether benzotriazole derivatives as potentiators of metabotropic glutamate receptors. US 2012/0135, 977
157. Beshore DC, Garbaccio RM, Kuduk SD et al (2012) Preparation of aminomethyl biaryl benzotriazole derivatives as potentiators of mGluR2. WO 2012/151, 136
158. Beshore DC, Kuduk SD (2012) Preparation of hydroxymethyl biaryl benzotriazole derivatives as potentiators of metabotropic glutamate receptors. WO 2012/151, 140
159. Beshore DC, Kuduk SD (2012) Preparation of cyclohexene benzotriazole derivatives for treatment or prevention of neurological and psychiatric disorders. WO 2012/151, 138
160. Kuduk SD, Skudlarek JW (2012) Preparation of alkyne benzotriazole derivatives as metabotropic glutamate receptors. WO 2012/151, 139
161. Layton ME, Pero JE, Rodzinak KJ et al (2011) Preparation of imidazopyridin-2-one derivatives as potentiators of metabotropic glutamate receptors. WO 2011/034, 741
162. Fiji HD, Kelly MJ, Kern JC et al (2012) Preparation of imidazopyridin-2-one derivatives as potentiators of metabotropic glutamate receptors. WO 2012/174, 199
163. Arrington KL, Dudkin V, Layton ME et al (2011) Preparation of 5-substituted 1, 3-dihydro-2H-imidazo[4, 5-b]pyridine-2-one derivatives as positive allosteric modulators of mGluR2 therapy. WO 2011/156, 245
164. Dudkin V, Fraley ME, Arrington K et al (2012) Benzimidazolone derivatives as positive allosteric modulators of mGluR2 and their preparation and use for the treatment of neurological and psychiatric disorders. WO 2012/021, 382
165. Layton ME, Kelly MJ (2011) Substituted 1, 3-benzothiazol-2(3H)-ones and [1, 3]thiazolo [5, 4-b]pyridine-2(1H)-ones as positive allosteric modulators in mGluR2. WO 2011/137, 046
166. Layton ME, Kelly MJ, Hartingh TJ (2011) Preparation of benzothiadiazole and thiadiazolopyridine dioxides as positive allosteric modulators of mGluR2. WO 2011/109, 277